ArticleMolecular diversity2026
De novo generation and computational screening of dual-targeting short peptide inhibitors against PBP2b and PBP2x in drug-resistant Streptococcus Pneumoniae.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep learning has greatly advanced de novo protein design, yet its application to rational short peptide design remains underexplored. Here, we developed SPB-Seeker (Short Peptide Binder Seeker), an integrated pipeline combining deep learning-based generative models with computational chemistry screening to discover dual-target short peptide inhibitors. Using penicillin-binding proteins PBP2b and PBP2x from drug-resistant Streptococcus pneumoniae as targets, AFDesign, RFdiffusion, and BoltzGen were employed to generate an initial library of 1101 candidate sequences. Subsequently, ESM2 was employed to extract sequence embeddings for diversity analysis, which revealed distinct algorithmic biases among the three generative models, and was then used as the feature extractor of a prediction framework for early-stage toxicity screening. Candidates were further prioritized through molecular docking, tiered molecular dynamics simulations, and MM/PB(GB)SA binding free energy calculations. Three peptides, AFD1, BG3, and RFD2, showed high binding stability, with BG3 displaying the strongest dual-target binding, achieving binding free energies of - 52.777 kcal/mol for PBP2b and - 74.071 kcal/mol for PBP2x. Interestingly, quantum chemical calculations using cluster model and the Interaction Region Indicator (IRI) method analyses indicated that BG3 adopts a stable cyclic-like conformation when bound to PBP2x, driven by proline-induced turns, intramolecular hydrogen bonds, and terminal C-H···π interactions. Overall, SPB-Seeker provides an extensible computational framework for targeted short peptide binder discovery and offers a basis for subsequent affinity optimization and stability enhancement.
Indexed as
Identifiers
42693314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.